DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.

Date publication

décembre 2022

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HARLE Alexandre , Pr MERLIN Jean-Louis , Pr GRANDEMANGE Stéphanie , Dr GILSON Pauline , Dr LAMBERT Aurélien

Tous les auteurs :
Dardare J, Witz A, Betz M, Francois A, Meras M, Lamy L, Lambert A, Grandemange S, Husson M, Rouyer M, Demange J, Merlin JL, Harlé A, Gilson P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36568213

Résumé

Damage specific DNA binding protein 2 (DDB2) is an UV-indiced DNA damage recognition factor and regulator of cancer development and progression. DDB2 has dual roles in several cancers, either as an oncogene or as a tumor suppressor gene, depending on cancer localization. Here, we investigated the unresolved role of DDB2 in pancreatic ductal adenocarcinoma (PDAC).

Mots clés

biomarker, chemosensitivity, damage specific DNA binding protein 2, epithelial-to-mesenchymal transition, pancreatic ductal adenocarcinoma, prognosis

Référence

Front Oncol. 2022 12 8;12:1052163